Importance of early treatment in metastatic prostate cancer: a question of life or death

Fred Saad¹

Affiliations

Comment

Fred Saad. Lancet Oncol. 2019 May.

. 2019 May;20(5):609-611.

doi: 10.1016/S1470-2045(19)30155-X. Epub 2019 Apr 12.

Fred Saad¹

¹ Department of Urology, Centre Hospitalier de l'Université de Montréal, Montreal, QC H2X 0A9, Canada. Electronic address: fred.saad@umontreal.ca.

No abstract available

Comment on

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN. Fizazi K, et al. Lancet Oncol. 2019 May;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8. Epub 2019 Apr 12. Lancet Oncol. 2019. PMID: 30987939 Clinical Trial.